Clinical trial registry record

Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 31, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02623309
Last registry update
January 31, 2023
Status
Completed
Phase
Phase 3
Sponsor
Institut Paoli-Calmettes
Enrollment
108
Countries
France
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
108
Population
ALL · 55 Years to 70 Years
Duration
2016-02-23 to 2021-03-12
Intervention
Allogeneic (Allo) hematopoietic stem cell transplantation
Comparator
MUD graft
Outcomes measured
Event-free survival with death, relapse or occurrence of severe cGVHD as event whatever occurs first — 5 years; Engraftment: time to reach 0.5 x 109/l ANC, 20 x 109/l platelets and full donor lymphoid chimerism — 5 years; Acute and chronic GVHD cumulative incidences — 5 years; Non-relapse mortality cumulative incidence — 5 years; Relapse incidence — 5 years; Probabilities of overall survival and progression-free survival — 5 years; Evaluation of HRQL including patients who relapse — 5 years; Evaluation of procedure costs from beginning of search until death or two-year follow-up — 5 years
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Stem cells · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

stem cells
Read the original source →Export JSON